Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 75 of 5804
-
New bladder cancer combo aims to beat standard treatment
Disease control OngoingThe purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetreli…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New Two-Drug combo aims to stop leprosy spread in its tracks
Prevention Recruiting nowThere will be two study arms. Arm 1 will be the intervention arm in which there will be provided BE-PEP to all persons residing within 100 meters of an index case, to be repeated after four weeks for household contacts. Arm 2 will be the comparator arm in which the WHO recommende…
Phase: PHASE3 • Sponsor: Institute of Tropical Medicine, Belgium • Aim: Prevention
Last updated Jun 27, 2026 12:36 UTC
-
New combo treatment could improve outcomes in major stroke
Disease control CompletedTo assess the effect of intravenous tenecteplase plus endovascular thrombectomy (EVT) compared to EVT alone on 4.5 to 24 hours after stroke due to basilar artery occlusion.
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of University of Science and Technology of China • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New blood test aims to spot pancreatic cancer before It's too late
Diagnosis Recruiting nowThis study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC
-
New drug cocktail aims to stall ovarian cancer recurrence
Disease control OngoingGLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate recept…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Diabetes pill could slash heart attack risk in millions
Disease control OngoingASCEND PLUS is testing whether, for people with type 2 diabetes who have not previously had a heart attack or stroke, regularly taking a tablet called semaglutide can safely help to reduce heart attacks, strokes, mini-strokes, the need for any procedures to unblock or bypass an a…
Phase: PHASE4 • Sponsor: University of Oxford • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
CRISPR gene editing takes on blood cancers: new trial tests donor immune cells
Disease control Recruiting nowThis is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Twice-Yearly shot could prevent heart attacks in millions
Prevention OngoingCKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Prevention
Last updated Jul 08, 2026 00:00 UTC
-
New hope for liver cancer: triple therapy shows promise
Disease control CompletedTRIPLET HCC is a phase II-III trial that assess the effectivness of addition of ipilimumab to the combination atezolizumab-bevacizumab, on global survival and response to the treatment, for patients with advanced or metastatic hepatocellular carcinoma. The theoretical duration of…
Phase: PHASE2, PHASE3 • Sponsor: Federation Francophone de Cancerologie Digestive • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Supercharged immune cells take on HPV cancers
Disease control Recruiting nowThis is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers. Participants will receive a conditio…
Phase: PHASE2 • Sponsor: Christian Hinrichs • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill could offer hope for Hard-to-Treat breast cancer
Disease control OngoingA study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New pill takes on deadly leukemia in major trial
Disease control Recruiting nowA randomized,multicenter, open-label Phase III, clinical study is conducted to evaluate the clinical benefit Clifutinib in Chinese patients with relapsed/ refractory (R/R) FLT3-mutated AML as shown with overall survival compared to salvage chemotherapy, and also to investigate th…
Phase: PHASE3 • Sponsor: Sunshine Lake Pharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Could stem cells offer a lifeline for sudden liver failure?
Disease control CompletedThe goal of this clinical trial is to learn if CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection (hereinafter referred to as CG-BM1) can treat acute-on-chronic liver failure (ACLF) patients. Main purposes of this clinical trial are: * To evaluate the safety and…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New combo aims to boost CAR T-Cell success in tough lymphomas
Disease control OngoingThis research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabrutinib in combination with lis…
Phase: PHASE2 • Sponsor: Patrick C. Johnson, MD • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New pill may replace chemo for kids with brain tumors
Disease control OngoingThis is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapid…
Phase: PHASE3 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could a stem cell transplant tame VEXAS syndrome?
Disease control Recruiting nowBackground: Allogeneic hematopoietic stem cell transplant involves taking blood stem cells from a donor and giving them to a recipient. The transplants are used to treat certain diseases and cancers. Researchers want to see if the transplant can treat VEXAS Syndrome. Objective:…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New Dual-Target CAR-T therapy offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis is a multicenter, single arm, open-label study. The purpose of the study is to evaluate safety of Prizloncabtagene Autoleucel (Prizlon-cel) and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of Prizlon-cel (Phase 2) in patients with rel…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai AbelZeta Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Peanut patch could let allergic kids tolerate small amounts of peanut
Disease control OngoingThe primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.
Phase: PHASE3 • Sponsor: DBV Technologies • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can a simple drug save Kids' hearing during chemo?
Disease control Recruiting nowThis phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back after treatment. Subjects with low-risk m…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
One-Time gene injection aims to halt rare eye disease
Disease control OngoingThe purpose of this study was to evaluate the safety and efficacy of ZVS101e administered by subretinal injection in subjects with Bietti's crystalline dystrophy (BCD) and to select the optimal effective dose.
Phase: PHASE1, PHASE2 • Sponsor: Chigenovo Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC